PKM and non-small cell lung carcinoma: Shikonin promoted cell cycle arrest and death by blocking the PKM2/STAT3/cyclinD1 signaling pathway in human NSCLC cell lines A549, H1299, H1975 and HCC827, thereby increasing the anticancer impact of gefitinib both in vitro and in vivo (Tang et al., 2018).